Psilocybin trials show poorer control group outcomes compared to SSRIs and esketamine, potentially inflating perceived efficacy due to expectancy bias and functional unblinding. Control group response ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback